Last reviewed · How we verify
NCT06550271
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
trial testing Rapamycin in Aging in 67 participants. Completed in 15 December 2023.
15 December 2023
Quick facts
| Lead sponsor | AgelessRx |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 67 |
| Start date | 25 April 2023 |
| Primary completion | 15 December 2023 |
| Estimated completion | 15 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Rapamycin — full drug profile →
Conditions studied
- Aging — all drugs for Aging →
Sponsor
AgelessRx — full company profile →
Who can join
Adults 40 to 120, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Senescent macrophages in tumor: phenotypes, roles, and interventions.
Shen W, Huang Y, Yang X, Zhang Y, et al · · 2025 · cited 1× · PMID 41053023 · DOI 10.1038/s41419-025-08000-5
Verify or expand the search:
- PubMed search for NCT06550271
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rapamycin
Trials testing the same drug.
- NCT06743503 — UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies · Phase 1 · recruiting
- NCT06257420 — Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions · enrolling by invitation
- NCT05342519 — Daily Topical Rapamycin for Vitiligo · Phase 2 · active not recruiting
- NCT04736589 — Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway · Phase 3 · not yet recruiting
- NCT04488601 — Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study · Phase 2 · completed
Other recruiting trials for Aging
Currently open trials in the same condition.
- NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
- NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging · recruiting
- NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in · NA · recruiting
- NCT07525453 — Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults · NA · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other AgelessRx trials
Trials by the same sponsor.
- NCT07092605 — Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures · EARLY_PHASE1 · enrolling by invitation
- NCT06301529 — The Efficacy and Tolerability of Canagliflozin in Healthy Individual · Phase 4 · completed
- NCT05542849 — The Efficacy and Tolerability of Acarbose in Healthy Individuals · Phase 4 · completed
- NCT05307627 — The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging · withdrawn
- NCT04604704 — Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06550271 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AgelessRx
- Last refreshed: 13 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06550271.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing